Navigation Links
InspireMD Files At-the-Market Offering and Shelf Registration Statement
Date:10/24/2013

BOSTON, Oct. 24, 2013 /PRNewswire/ -- InspireMD Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection stents, announced today that it has filed a $75 million shelf registration statement on Form S-3 with the Securities and Exchange Commission (the "SEC").  Once declared effective by the SEC, the shelf registration statement would permit the Company to sell, from time to time over the next three years, up to $75 million in aggregate value of its common stock, preferred stock and/or warrants, either individually or in units. The shelf registration statement is intended to provide the Company with flexibility to access additional capital when market conditions are appropriate.

The registration statement has been filed with the SEC, but has not yet become effective. Any offers, solicitations of offers to buy, or sales of the securities will only be made once the shelf registration statement has been declared effective by the SEC, including any prospectuses and prospectus supplements. These securities may not be sold, nor may offers to buy be accepted prior to the time that the registration statement becomes effective.

In addition, the Company announced today that it has filed a prospectus as part of the shelf registration statement to sell, of the $75 million of securities being registered, up to an aggregate of $40 million of its common stock (the "Shares") through an "at-the-market" ("ATM") offering.  If utilized, the Shares would be offered through MLV & Co. LLC ("MLV") as sales agent. MLV, at the Company's discretion and instruction, will use its commercially reasonable efforts to sell the Shares at market prices from time to time, including sales made directly on the NYSE MKT.  The Company currently intends to use the proceeds from any sales related to the ATM offering to support general corporate purposes, including th
'/>"/>

SOURCE InspireMD
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. InspireMD Elects Sol J. Barer, Ph.D. Chairman of the Board of Directors
2. InspireMD Appoints Dr. James Barry to Its Board of Directors
3. InspireMD to Present at JMP Securities Healthcare Conferenceon July 12th in New York
4. InspireMD to Present at JMP Securities Healthcare Conference on July 12th in New York
5. InspireMD Reports 2012 Fiscal Year Results
6. InspireMD Postpones $40 Million Registered
7. Michael Berman Joins InspireMD Board
8. InspireMD Hires Vice President of Corporate Development
9. InspireMD To Participate In Benchmark Investor Conference On May 30th
10. InspireMD Secures Financing to Accelerate Advancements in Product Development and Adopts a One Year Stockholder Rights Plan
11. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... PARSIPPANY, N.J. , Aug. 31, 2014 ... New Drug Discovery program in Anti-Infective research when two ... the coveted Qualified Infectious Disease Product (QIDP) status from ... granted to drugs which act against pathogens which have ... and are identified by Centre for Disease Control (a ...
(Date:8/29/2014)... DIEGO, Aug. 29, 2014  Pfenex Inc. (NYSE ... the development of high-value and difficult to manufacture ... update and reported financial results for the second ... the successful completion of our initial public offering, ... our biosimilar product candidates, derived from our proprietary ...
(Date:8/29/2014)... VANCOUVER , Aug. 29, 2014 /PRNewswire/ - ... (OTCQX: ICOTF), today reported financial results for the ... specified otherwise, are expressed in Canadian dollars and ... Second Quarter 2014 Highlights , ... visual acuity (VA) primary endpoint for subjects enrolled ...
(Date:8/29/2014)... 29, 2014 Intrinsic Imaging, an ... GAMP® 5 compliant imaging core lab, announced today ... II clinical trial to assess a new treatment ... trial, Intrinsic Imaging will provide comprehensive imaging core ... and charter development, site qualification, site training and ...
Breaking Biology Technology:U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2
... Pharma, Inc.,(Nasdaq: IDMI ), a biotechnology company focused ... Timothy P. Walbert,president and chief executive officer, will present ... Diego on Thursday, November 1, 2007,at 2 p.m. PDT ... webcast of the presentation will be available live and ...
... Immunosyn,Corporation (OTC Bulletin Board: IMYN) has announced the ... Financial and Accounting Officer.,Immunosyn,s former Chief Financial and ... as the company,s Chairman of the Board and,further ... believe that the platform technology and its resulting,biopharmaceutical ...
... Md., Oct. 29 /PRNewswire/,-- Cambridge Antibody Technology ... to,reflect AstraZeneca,s vision for its worldwide biologics ... resources and expertise from CAT, the pre-,existing ... AstraZeneca,Group, under the "MedImmune" name. With this ...
Cached Biology Technology:IDM Pharma to Present at BIOCOM Investor Conference 2IDM Pharma to Present at BIOCOM Investor Conference 3Immunosyn Corporation Names G. David Criner as CFO 2AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune 2
(Date:9/2/2014)... study published in the September 2014 issue of ... Child and Adolescent Psychiatry found that children ... an increased risk of developing diabetes if they ... the nationwide Danish registers, a group of researchers ... University Hospital, Denmark, studied 48,299children and adolescents with ...
(Date:9/2/2014)... N.C. -- When you accidentally touch a hot oven, ... the basic neural circuits involved in sensing and responding ... the molecular players. , Duke researchers have made a ... involved in pain in worms, and have built a ... 2 in Nature Communications , may help direct ...
(Date:9/1/2014)... Mass-- Conventional wisdom has long held that corals ... coral reefs are passive organisms that rely ... such as nutrients and oxygen. But now scientists ... (WIS) in Israel have found that they are ... water into turbulent patterns that greatly enhance their ...
Breaking Biology News(10 mins):Risk of diabetes in children and adolescents exposed to antipsychotics 2Surprising new role for calcium in sensing pain 2Surprising new role for calcium in sensing pain 3Nature's tiny engineers 2Nature's tiny engineers 3
... Jan. 7, 2014 DigitalPersona, Inc., a trusted ... that its TouchChip® TCS1 sensor is the only ... the Ministry of Public Security under general technical ... for the China Resident Identity Card.  Miaxis Biometrics ...
... FL (January 6, 2014) Of the 1.9 million species ... 1.3 million are invertebrates. They have served as model organisms ... of the important role of invertebrates in science including sea ... and Loligo for neurobiology research, the fruit fly ...
... 2014) Autism Speaks, the world,s leading autism science ... $2.7 million for the funding of 13 new research ... address Autism Speaks, Early Access to Care initiative to ... to high-quality early intervention for all children affected by ...
Cached Biology News:Fingerprint Readers with DigitalPersona Silicon-based Sensors Certified for China Resident Identity Card 2Fingerprint Readers with DigitalPersona Silicon-based Sensors Certified for China Resident Identity Card 3New organization brings together top researchers to sequence the genomes of invertebrates 2New organization brings together top researchers to sequence the genomes of invertebrates 3Autism Speaks awards nearly $2.7 million for new research projects 2Autism Speaks awards nearly $2.7 million for new research projects 3Autism Speaks awards nearly $2.7 million for new research projects 4
Mouse monoclonal antibody raised against a partial recombinant CALCOCO2. NCBI Entrez Gene ID = CALCOCO2...
Mouse monoclonal to Casein Kinase 2 beta ( Abpromise for all tested applications). entrezGeneID: 1460 SwissProtID: P13862...
...
Mouse monoclonal antibody raised against a partial recombinant ZNF167. NCBI Entrez Gene ID = ZNF167...
Biology Products: